Примери за използване на Repeat-dose на Английски и техните преводи на Български
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Computer
Safety pharmacology and repeat-dose toxicity.
In single- and repeat-dose studies, the Cmax and AUC of rimonabant were similar in healthy Japanese.
In monkeys, pomalidomide was evaluated in repeat-dose studies of up to 9 months in duration.
In a 39-week repeat-dose toxicity study in dogs NOAEL of 300 mg/kg/day was determined.
In the dog, foamy macrophages were observed in lymphoid tissue of various organs during repeat-dose toxicity studies.
Repeat-dose toxicology studies identified the liver and bone marrow as target organs in the dog.
Depletion of lymphoid organs was observed in repeat-dose toxicity studies in rats and cynomolgus monkeys.
Repeat-dose toxicity studies longer than 5 days, reproductive toxicity studies, and carcinogenicity studies.
Mean(CV%) AUC metabolite/parent drug ratio for N-desmethyl apalutamide following repeat-dose administration was about 1.3(21%).
Repeat-dose toxicity studies in rat and dog showed mainly dose-limiting pharmacological effects, such as sedation.
Non-clinical data reveal no special hazards for human based on conventional studies of safety pharmacology, repeat-dose toxicity, or genotoxicity.
Based on repeat-dose toxicity studies in male animals, Alunbrig may cause reduced fertility in males(see section 5.3).
Results from both studies show that renal function status had no marked effect on the exposure of carfilzomib following single or repeat-dose administration.
The findings made in repeat-dose toxicity studies conducted with Xeomin were mainly related to its pharmacodynamic action.
A slightly increased incidence of thickening of the atrioventricular valves of the heart was seen in the 26 week repeat-dose toxicity study in rats.
Effects observed in repeat-dose toxicity studies were mainly due to the exaggerated pharmacodynamic activity of rivaroxaban.
However reversible hypospermia and testicular vacuolation andimmaturity of the ovaries were observed in a repeat-dose toxicity study with fenofibric acid in young dogs.
In repeat-dose toxicity studies(14-weeks and 53-weeks) of intrathecal administration to juvenile cynomolgus monkeys, nusinersen was well tolerated.
Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeat-dose toxicity, genotoxicity, carcinogenic potential, or toxicity to reproduction.
In 1-month and 3-month repeat-dose toxicology studies in monkeys, there were no notable effects in the female reproductive organs.
Sufentanil has been shown to induce opioid-like effects in a variety of laboratory animals(dogs, rats, guinea pigs, hamsters)at doses above those inducing analgesia and in two repeat-dose studies with sufentanil sublingual tablets administered buccally in Golden Syrian hamster.
In a 26-week repeat-dose toxicity study in rats a No-Observed Adverse Effect Level(NOAEL) of 50 mg/kg/day was determined.
Ivacaftor impaired fertility and reproductive performance indices in male and female rats at 200 mg/kg/day(yielding exposures approximately 11 and 7 times, respectively, those obtained with the maximum recommended human dose of the ivacaftor component of Orkambi based on summed AUCs of ivacaftor andits metabolites extrapolated from Day 90 exposures at 150 mg/kg/day in the 6-month repeat-dose toxicity study and gestation Day 17 exposures in the pilot embryofoetal development study in this species) when dams were dosed prior to and during early pregnancy.
Repeat-dose toxicity studies in rabbits revealed an inhibitory effect of delamanid and/or its metabolites on vitamin K-dependent blood clotting.
Mean metabolite to parent AUC ratios following repeat-dose administration were 0.9, 11 and 0.7 for hydroxy-, carboxy-, and desmethyl-dabrafenib, respectively.
Repeat-dose toxicity studies have established that the NOEL(No Observed Effect Level) is about 95 mg zinc/kg body weight(about 48 times the human therapeutic dose).
A clinical interaction study performed in healthy subjects showed that co-administration of repeat-dose anagrelide 1 mg once daily and acetylsalicylic acid 75 mg once daily may enhance the anti-platelet aggregation effects of each active substance compared with administration of acetylsalicylic acid alone.
Repeat-dose toxicity studies have shown that primary target organs were tissues that undergo rapid cell division: bone marrow, lymphoid tissue, testes and digestive tract.
High serum prolactin levels in long-term repeat-dose studies in female rats were associated with effects on bones, adrenal glands, and reproductive tissues.
In repeat-dose toxicity studies, no concern in terms of fertility was raised from pathological examination of reproductive organs in rats and monkeys.